Implications of the Pharmacovigilance Risk Assessment Committee recommendations for the treatment of genitourinary syndrome
| Autor: | George Gregory Buttigieg, Kirill Micallef-Stafrace |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Genitourinary system business.industry Low dose MEDLINE General Medicine Limiting 030204 cardiovascular system & hematology Risk Assessment Pharmacovigilance 03 medical and health sciences 0302 clinical medicine Family medicine Humans Medicine Female 030212 general & internal medicine business Risk assessment |
| Zdroj: | British Journal of Hospital Medicine. 82:1-3 |
| ISSN: | 1759-7390 1750-8460 |
| DOI: | 10.12968/hmed.2020.0568 |
| Popis: | The European Medicines Agency's Pharmacovigilance Risk Assessment Committee has issued statements regarding limiting the use of high-dose oestradiol creams by women experiencing the genitourinary syndrome of menopause, and such statements carry much medicolegal weight. Although a low dose is most often used, some clinicians opt to use higher dose creams with close monitoring of the patient. The committee should publish the evidence behind these statements or amend its official position. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|